» Articles » PMID: 23161722

Investigation of the BRAF V600E Mutation by Pyrosequencing in Lymphoproliferative Disorders

Overview
Specialty Pathology
Date 2012 Nov 20
PMID 23161722
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

The presence of the BRAF c.1799T>A V600E mutation was recently described in cases of hairy cell leukemia (HCL) but not in other common lymphomas. However, many uncommon subtypes of lymphoma have not been studied. We designed a BRAF pyrosequencing assay specific for the V600E mutation, which has a sensitivity of 5% and is applicable to paraffin-embedded tissue. DNA was sequenced in 9 cases of HCL; 6 cases of variant HCL; 10 cases each of nodal marginal zone lymphoma (NMZL), extranodal marginal zone lymphoma (ENMZL), posttransplantation lymphoproliferative disorder (PTLD), and large granular lymphocyte (LGL) proliferations; 11 cases of peripheral T-cell lymphoma (PTCL); and 12 cases of anaplastic large cell lymphoma (ALCL). All (100%) cases of HCL were positive for BRAF mutations. No mutations were identified in variant HCL, NMZL, ENMZL, PTLD, PTCL, ALCL, or LGL proliferations. Among lymphoproliferative disorders, BRAF mutations are restricted to HCL.

Citing Articles

Circulating tumor DNA in lymphoma: technologies and applications.

Fu L, Zhou X, Zhang X, Li X, Zhang F, Gu H J Hematol Oncol. 2025; 18(1):29.

PMID: 40069858 PMC: 11900646. DOI: 10.1186/s13045-025-01673-7.


Recent advances in therapeutic strategies of Erdheim-Chester disease.

Doke R, Lokhande R, Chande K, Vinchurkar K, Prajapati B Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 39836251 DOI: 10.1007/s00210-024-03769-2.


BRAF Mutation Analysis in Fine-Needle Aspiration Cytology of Fixed Slide Specimens in Patients with Papillary Thyroid Carcinoma.

Cheraghi S, Honardoost M, Abdolmaleki F, Khamseh M Med J Islam Repub Iran. 2024; 38:83.

PMID: 39678775 PMC: 11644031. DOI: 10.47176/mjiri.38.83.


Investigations of the novel checkpoint kinase 1 inhibitor SRA737 in non-small cell lung cancer and colorectal cancer cells of differing gene status.

Duabil A, Cooper C, Aldujaily E, Halford S, Hirschberg S, Katugampola S Explor Target Antitumor Ther. 2024; 4(5):1210-1226.

PMID: 38214010 PMC: 10776598. DOI: 10.37349/etat.2023.00193.


Evaluation of the expression levels of BRAF mRNA in primary tumors of thyroid cancer using an ultrasensitive mutation assay.

Tran T, Dang K, Pham Q, Nguyen U, Trinh N, Hoang L BMC Cancer. 2020; 20(1):368.

PMID: 32357861 PMC: 7195771. DOI: 10.1186/s12885-020-06862-w.